Predictors of Major Adverse Limb Events After Iliac Artery Stenting
Official title: Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort Study (PREMISE-ILIAC Study)
Run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · NCT07672249 · Data updated 2026-11-12
This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 98 (estimated) |
| Sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio Academic / other |
| Locations | 1 site (Milan, Mi) |
| Status | Recruiting |
| Started | June 16, 2026 |
| Main results expected | July 1, 2026 |
| Study ends | July 16, 2026 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT07672249 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with symptomatic peripheral arterial disease involving the iliac arteries who are treated with endovascular iliac artery stenting at the participating center.
✕Probably not a fit
Patients with non-iliac targets, prior iliac stenting, or those undergoing open surgical revascularization are not the focus of this analysis and may not benefit from study findings relevant to iliac stenting outcomes.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective, single-center observational study of adults undergoing endovascular iliac artery stenting. It aims to identify patient- and lesion-related factors that predict Major Adverse Limb Events in a real-world population with substantial comorbidity. Outcomes will include limb-related adverse events after the procedure and will be analyzed in relation to baseline characteristics and imaging findings. The study uses data from routine clinical care at a high-volume Italian center to generate insights applicable to everyday practice. No interventional assignment is made; the focus is on observational associations in real-world care.
Why it matters
Potential benefit: Insights from this study could help clinicians better identify patients at higher risk for MALE after iliac stenting and tailor follow-up and management accordingly.
How similar studies have gone: Previous work has explored predictors of limb events in endovascular populations, but real-world, unselected cohorts for iliac stenting remain limited, making this study relatively novel in its scope.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Adult patients aged ≥18 years, of both male and female sex * Presence of haemodynamically significant stenosis or occlusion of the common iliac artery (CIA) and/or external iliac artery (EIA), documented by computed tomography angiography, magnetic resonance angiography, or diagnostic angiography * Symptomatic peripheral artery disease, including lifestyle-limiting intermittent claudication (Rutherford category 2-3) or chronic limb- threatening ischaemia (CLTI; Rutherford category 4-6), refractory to optimal medical therapy * Treatment with endovascular iliac artery stenting (covered or uncovered; balloon-expandable or self-expanding devices) as the primary revascularisation strategy * De novo iliac lesions only * Availability of complet Exclusion Criteria: Primary open surgical revascularisation of the iliac axis (e.g., aorto- bifemoral bypass or endarterectomy). * Previous stenting of the target iliac segment (in-stent restenosis cases excluded). * Aorto-iliac aneurysmal disease as the primary indication for treatment (including EVAR or fenestrated endografts). * Hybrid procedures with concomitant infrainguinal bypass surgery. * Incomplete clinical, procedural, or follow-up data preventing assessment of study endpoints. * Loss to follow-up without documented clinical outcomes.
Where it's running
-
IRCCS Galeazzi Sant'Ambrogio Hospital
Milan, Mi, Italy Recruiting
Study contacts
- Study coordinator: Luca Galassi, MD
- Email: luca.galassi@unimi.it
- Phone: +393458013083
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Imaging plaque activity across the body in people with symptomatic peripheral arterial disease
This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.
-
Esprit BTK everolimus-eluting resorbable scaffold in infrapopliteal artery disease for CLTI
This study tests whether the Esprit BTK Everolimus Eluting Resorbable Scaffold works in real-world patients with chronic limb-threatening ischemia and heavily calcified infrapopliteal arteries.
-
Orbital Atherectomy to Prep Calcified Leg Arteries in CLTI Patients
This Europe-wide study tests how well orbital atherectomy helps patients with chronic limb-threatening ischemia when opening heavily calcified leg arteries.
-
Personalised multicomponent exercise program for peripheral arterial disease
This trial tests whether a personalised, continuously monitored exercise program using heart-rate and muscle-oxygen sensors can help people with peripheral arterial disease and intermittent claudication walk farther and have less leg pain.
-
Using mobile health data to improve recovery after bypass surgery for leg ischemia
This study is testing if using health data from a smartwatch can help older patients recover better and move more easily after bypass surgery for leg problems.
-
Comparison of a new endoprosthesis to traditional stenting for iliac artery disease
This study is testing a new type of stent for people with iliac artery disease to see if it works better than the traditional metal stents in improving blood flow and relieving symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.